Abstract:Kinase inhibitors are widely used in antitumor research, but there are still many problems such as drug resistance and off-target toxicity. A more suitable solution is to design a multitarget inhibitor with certain selectivity. Herein, computational and experimental studies were applied to the discovery of dual inhibitors against FGFR4 and EGFR. A quantitative structure–property relationship (QSPR) study was carried out to predict the FGFR4 and EGFR activity of a data set consisting of 843 and 5088 compounds, respectively. Four different machine learning methods including support vector machine (SVM), random forest (RF), gradient boost regression tree (GBRT), and XGBoost (XGB) were built using the most suitable features selected by the mutual information algorithm. As for FGFR4 and EGFR, SVM showed the best performance with R2test-FGFR4 = 0.80 and R2test-EGFR = 0.75, demonstrating excellent model stability, which was used to predict the activity of some compounds from an in-house database. Finally, compound 1 was selected, which exhibits inhibitory activity against FGFR4 (IC50 = 86.2 nM) and EGFR (IC50 = 83.9 nM) kinase, respectively. Furthermore, molecular docking and molecular dynamics simulations were performed to identify key amino acids for the interaction of compound 1 with FGFR4 and EGFR. In this paper, the machine-learning-based QSAR models were established and effectively applied to the discovery of dual-target inhibitors against FGFR4 and EGFR, demonstrating the great potential of machine learning strategies in dual inhibitor discovery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00652?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00652</a>.Supporting Methods: Y-randomization test (p 2). Supporting Figures: Figure S1. The relationship between Q2 and the number of descriptors for FGFR4. Figure S2. Distribution of Q2 of randomized models compared with the true model in the Y-randomization test. Figure S3. Correlograms between each important descriptor and permeability values of two activity prediction modeling: (a) FGFR4, (b) EGFR. Figure S4. Comparison of the molecular similarity between the training set and the external set: (a) FGFR4 data set, (b) EGFR data set. Figure S5. Structures of compounds 1–3. Figures S6 and S7. The chemical structures of modeling molecules of the FGFR4/EGFR activity prediction model. Figure S8. The chemical structures of 23 compounds external verification set. Figure S9. Docking results of FGFR4 and EGFR. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00652/suppl_file/ci0c00652_si_001.pdf">PDF</a>)Table S1. Experimental and predicted IC50 values of FGFR4 of the whole data set that consisted of 843 compounds. Table S2. Experimental and predicted IC50 values of EGFR of the whole data set that consisted of 5088 compounds. Table S3. Detailed information for the external validation set. Table S4. Statistical analysis of 180 descriptors selected in FGFR4 activity prediction. Table S5. Statistical analysis of 280 descriptors selected in EGFR activity prediction. Table S6. Detailed information on the most essential variables for FGFR4 prediction activity modeling. Table S7. Detailed information on the most essential variables for EGFR prediction activity modeling. Table S8. The original data for cross-docking of FGFR4 and EGFR. Table S9. Residue-specific binding free energies of FGFR4 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UXQ">4UXQ</a>) and compound 1. Table S10. Residue-specific binding free energies of EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>) and compound 1. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00652/suppl_file/ci0c00652_si_002.xlsx">XLSX</a>)This article has not yet been cited by other publications.

High Rates of Inducible Clindamycin Resistance among Prenatal Group B Streptococcal Isolates in One Northwest Louisiana Academic Medical Center

TNFipred: a classification model to predict TNF-α inhibitors

Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

Abstract 4910: AI predicts drug response from the genomic features of cells and the kinase activity changes induced by compounds

GraphEGFR: Multi‐task and transfer learning based on molecular graph attention mechanism and fingerprints improving inhibitor bioactivity prediction for EGFR family proteins on data scarcity

Virtual Screening, Molecular Dynamics, MM-PBSA and In-silico Studies in Search of Potent Novel Fibroblast Growth Factor Receptors 4 Inhibitor

Predicting Response to FLT3 Inhibitors Using Genomics-Based Computational Bio-Simulation Platform

Influencing factors on false positive rates when classifying tumor cell line response to drug treatment

MLASM: Machine learning based prediction of anticancer small molecules

Abstract 3527: Application of a deep learning based drug sensitivity prediction model on a novel anticancer drug

Integrated ML-Based Strategy Identifies Drug Repurposing for Idiopathic Pulmonary Fibrosis

Identification of new potential candidates to inhibit EGF via machine learning algorithm

PharmaNet: Pharmaceutical discovery with deep recurrent neural networks

In Silico Prediction of Androgenic and Nonandrogenic Compounds Using Random Forest

Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study

Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth

Machine learning based personalized drug response prediction for lung cancer patients

From deep learning to the discovery of promising VEGFR‐2 inhibitors

Ethnomedicine claim directed in-silico prediction of epidermal growth factor receptor kinase antagonist: an untapped reservoir of prospective anticancer agents

A Novel Artificial Intelligence Protocol for Finding Potential Inhibitors of Acute Myeloid Leukemia.